… The expert panel analyzed three studies regarding the use of intermittent ICS therapy with
or without albuterol and daily ICS which showed no difference in the symptoms of asthma …

… updates to the GOLD guidelines emphasize the use of combination LABA and LAMA
bronchodilators for … , which are likely to become the principle therapy for many patients with COPD. …

… It is important to remember that in real life practice, it is the exception to treat a patient only
to prevent exacerbations; the vast majority of time we optimize bronchodilator therapy to …

… Sustained-release theophylline is a mild to moderate bronchodilator used as an alternative,
although not preferred, adjunctive therapy with inhaled corticosteroids. Theophylline may …

… significant, demonstrated that inhaled therapies (long-acting bronchodilators, inhaled
corticosteroids, or combination bronchodilator and corticosteroid therapy) reduced the annual …

… bronchodilator therapy in a single molecule and these drugs were shown to be beneficial in
terms of bronchodilation … : a clinical practice guideline update from the American college of …

… of bronchodilation explains why all guidelines highlight that inhaled bronchodilators are still
… Respiratory Society (ERS) guidelines conclude that no sufficient evidence exists to support …

… updates did not address biological therapies because at the time that a decision regarding
which topics to update … , and spirometry, including bronchodilator responsiveness testing, or …

… The next therapeutic step is dual bronchodilator therapy; the combination of LABA and LAMA
offers an added functional benefit, with less need for rescue medication and improvement …

… obtained, the patient is administered a bronchodilator (eg, albuterol), and the test is repeated.
… of therapy as the GINA guidelines. However, the main difference in the updated treatment …